Thomas James Kipps, MD, PhD, discusses the role of later generation and newer generation burton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia.
Thomas James Kipps, MD, PhD, deputy director of research operations for UC San Diego Moores Cancer Center at UC San Diego Health, discusses the role of older generation and newer generation Bruton’s tyrosine kinase inhibitor’s (BTKi) for patients with chronic lymphocytic leukemia (CLL).
As a part of the Society of Hematology Oncology 2022 meeting, Kipps looked ahead to the wider landscape of CLL and how new generation BTKis have built on previous generations of treatment.
In an interview with Targeted OncologyTM, Kipps discusses overcoming treatment resistance in this patient population and how BTK inhibitors like ibrutinib (Imbruvica), acalabrutinib (Calquence), zanubrutinib (Brukinsa), work to do that. Since the accelerated approval of ibrutinib in 2014, these BTK inhibitors have opened targeted treatment for patients with CLL who may have certain mutations or other factors that impact their treatment plan.
0:07 | In the case of the BTK inhibitors, we know that the covalent inhibitors are very much affected by a specific mutation in BTK at position 481, which, when it happens, prevents the drug from binding and forming a chemical bond with BTK. If you interchange between the different drugs, you're not going to have success in treating that patient if that mutation exists. I will say this [though], that ibrutinib does have some activity against the cells that have this mutation in them, although the cells may be coming up, but you can keep patients almost in check, but the some of the newer BTKs, such as acalabrutinib or perhaps zanubrutinib, may be less effective in holding down that clone.
0:50 | So sometimes, one can buy some time by maybe switching over to Ibrutinib if you don't have access to the noncovalent inhibitors, which I think that's important to note. I [also] think that if you do have such resistance, obviously you have to look at either these 3rd generation BTK inhibitors such as the non-covalent inhibitors, or perhaps to try a venetoclax based regimen that can be effective, along with maybe perhaps an anti-CD20 [drug] if you have to debulk the tumor to prevent or mitigate the risk of tumor lysis [syndrome].
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More